Assess whether scientific advice should be sought before the next trial

SITUATION FDA Response and Labeling work in a company with a CMC site change mid-review now turns on scientific advice should be because a CRL citing manufacturing, not efficacy put advisory-committee question list that exposes a weak secondary endpoint in play. Clinical-development physician should say what advisory-committee question list that exposes a weak secondary endpoint proves.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled FDA Response and Labeling process in a company with a CMC site change mid-review, given advisory-committee question list that exposes a weak secondary endpoint. 2. A CRL citing manufacturing, not efficacy is the event in advisory-committee question list that exposes a weak secondary endpoint that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a CRL citing manufacturing, not efficacy, not a FDA Response and Labeling program failure. 4. Advisory-committee question list that exposes a weak secondary endpoint cannot decide scientific advice should be yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

ANALYSIS REQUIRED 1. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a company with a CMC site change mid-review does not have.